CA3148592A1 - Selective estrogen receptor degrader - Google Patents
Selective estrogen receptor degrader Download PDFInfo
- Publication number
- CA3148592A1 CA3148592A1 CA3148592A CA3148592A CA3148592A1 CA 3148592 A1 CA3148592 A1 CA 3148592A1 CA 3148592 A CA3148592 A CA 3148592A CA 3148592 A CA3148592 A CA 3148592A CA 3148592 A1 CA3148592 A1 CA 3148592A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- cancer
- less
- chromen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029554 | 2019-07-22 | ||
| IN201921029554 | 2019-07-22 | ||
| PCT/IB2020/056914 WO2021014386A1 (en) | 2019-07-22 | 2020-07-22 | Selective estrogen receptor degrader |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3148592A1 true CA3148592A1 (en) | 2021-01-28 |
Family
ID=71842730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3148592A Pending CA3148592A1 (en) | 2019-07-22 | 2020-07-22 | Selective estrogen receptor degrader |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) * | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| US12391667B2 (en) | 2019-07-22 | 2025-08-19 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
| PE20241731A1 (es) * | 2022-02-01 | 2024-08-19 | Lilly Co Eli | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno |
| CN119176799B (zh) * | 2024-09-19 | 2025-10-03 | 晨伫(杭州)生物科技有限责任公司 | 色烯衍生物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| DE69023906T2 (de) | 1990-08-09 | 1996-04-11 | Council Scient Ind Res | Benzopyrane und Verfahren zu deren Herstellung. |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
| US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
| AU8102398A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | (dl)-2,3-diaryl-2h-1-benzopyrans |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EP2791132A4 (en) | 2011-12-14 | 2015-08-05 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| BR112014014767A2 (pt) | 2011-12-16 | 2017-06-13 | Olema Pharmaceuticals Inc | novos compostos de benzopirano, composições e usos dos mesmos |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| BR112015030595A2 (pt) * | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| CN103879283B (zh) * | 2014-03-10 | 2019-01-15 | 浙江吉利汽车研究院有限公司 | 一种电动车辆 |
| CN107406433A (zh) * | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的2,3‑二苯基色烯的衍生物 |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| US10865199B2 (en) * | 2015-10-27 | 2020-12-15 | Sun Pharma Advanced Research Company Limited | Heterocyclic antiestrogens |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
-
2020
- 2020-07-22 US US16/936,022 patent/US11014915B2/en active Active
- 2020-07-22 JP JP2022504655A patent/JP2022541938A/ja active Pending
- 2020-07-22 BR BR112022001285A patent/BR112022001285A2/pt not_active IP Right Cessation
- 2020-07-22 AU AU2020317099A patent/AU2020317099A1/en not_active Abandoned
- 2020-07-22 CA CA3148592A patent/CA3148592A1/en active Pending
- 2020-07-22 CN CN202080053315.6A patent/CN114302879A/zh active Pending
- 2020-07-22 WO PCT/IB2020/056914 patent/WO2021014386A1/en not_active Ceased
- 2020-07-22 MX MX2022001013A patent/MX2022001013A/es unknown
- 2020-07-22 EP EP20747136.8A patent/EP4003525A1/en not_active Withdrawn
- 2020-07-22 KR KR1020227005904A patent/KR20220046586A/ko not_active Ceased
- 2020-07-22 PE PE2022000135A patent/PE20221588A1/es unknown
- 2020-07-22 PH PH1/2022/550182A patent/PH12022550182A1/en unknown
-
2021
- 2021-05-05 US US17/308,501 patent/US20210261534A1/en not_active Abandoned
-
2022
- 2022-01-22 CL CL2022000156A patent/CL2022000156A1/es unknown
- 2022-01-23 IL IL290036A patent/IL290036A/en unknown
- 2022-01-25 ZA ZA2022/01157A patent/ZA202201157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202201157B (en) | 2023-07-26 |
| JP2022541938A (ja) | 2022-09-28 |
| BR112022001285A2 (pt) | 2022-03-22 |
| WO2021014386A1 (en) | 2021-01-28 |
| PE20221588A1 (es) | 2022-10-10 |
| MX2022001013A (es) | 2022-02-22 |
| US20210261534A1 (en) | 2021-08-26 |
| KR20220046586A (ko) | 2022-04-14 |
| US20210024504A1 (en) | 2021-01-28 |
| IL290036A (en) | 2022-03-01 |
| CN114302879A (zh) | 2022-04-08 |
| AU2020317099A1 (en) | 2022-02-24 |
| PH12022550182A1 (en) | 2022-11-14 |
| US11014915B2 (en) | 2021-05-25 |
| EP4003525A1 (en) | 2022-06-01 |
| CL2022000156A1 (es) | 2022-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11014915B2 (en) | Selective estrogen receptor degrader | |
| US20240226073A9 (en) | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | |
| CN1181077A (zh) | 苯并吡喃类化合物及其使用方法 | |
| CZ299721B6 (cs) | Lécivo pro lécení mocové inkontinence | |
| CN107406433A (zh) | 用于治疗癌症的2,3‑二苯基色烯的衍生物 | |
| CN105324115A (zh) | 雌激素受体调节剂及其用途 | |
| US20020072538A1 (en) | NMDA NR2B antagonists for treatment | |
| US20040110791A1 (en) | Novel arylaminopropane analogues and their use for the treatment of glaucoma | |
| Halama et al. | Improved process for the preparation of Montelukast: development of an efficient synthesis, identification of critical impurities and degradants | |
| TW202132294A (zh) | 雌激素受體調節劑之鹽及形式 | |
| US20080085930A1 (en) | Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate | |
| TW202300492A (zh) | 選擇性雌激素受體降解劑 | |
| US7655653B2 (en) | Tetrahydrobenzfluorene derivatives | |
| WO2004031125A1 (ja) | スピロ化合物、それを含有する医薬組成物及び該化合物の中間体 | |
| JP3294574B2 (ja) | 光学的に純粋なアンドロゲンメディエーター | |
| RU2855858C2 (ru) | ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА | |
| WO2025255358A1 (en) | Solid forms of posiphen d-tartrate and processes of preparation thereof | |
| CN101134739A (zh) | 新的β-内酰胺类化合物及其制备方法及其药物用途 | |
| HK40056233A (en) | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs | |
| US20100009949A1 (en) | Novel method | |
| HK1214532B (en) | Estrogen receptor modulator and uses thereof | |
| HK1124337A (en) | Nuclear receptor binding agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260109 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260129 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260204 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260309 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260330 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |